Mission
TMU Science (TMUS) thinks to implement the new findings and invention from Tokyo Medical University (TMU) in order to make a social contribution.
Vision
TMU Science thinks to implement the new findings and invention from Tokyo Medical University (TMU) in order to make a social contribution.
Incubation
TMU Scence conducts advanced R&D in various areas to address unmet medical and social needs in collaboration with Tokyo Medical University and several partners as the incubation labs. The followings are the asset of TMU Science.
1.
Plant exosome
2. Genome analysis (TMU-Decision, TMU-BRCA1/2)
3. AI pathology
4. 2nd Generation CAR-T
5. ES-derived regenerative medicine
About TMUS
| Name | TMU Science Co., Ltd. |
| Head Office | Van Vale 2F, 3-23-32, Kamikodanaka, Nakahara-ku, Kawasaki City, Kanagawa, 211-0053 Japan |
| Lab | 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, 160-8402 Japan At Tokyo Medical University, Department of Molecular Pathology |
| Direction | President & CEO; Mamoru Yanagimachi Board director; Kazuhiko Dannoue |
| Capital | Not disclosed |
| Main Bank | Kiraboshi Bank, Ltd. |
| Partnership | Tokyo Medical University、Vietnam National Cancer Hospital |
| Company history | Sep, 2018; Establishment of 2one2 Co., Ltd. Feb, 2021; Company name and CEO changed to TMU Science Co., Ltd. and Mamoru Yanagimachi, respectively. |
| Founder & Advisor | Masahiko Kuroda (Tokyo Medical University) Akihiro Umezawa (National Center for Child Health and Development) |
| HP | https://tmu-science |
Member
Kazuhiko Dannoue
Board director
Medical corporation Eiwakai
Tomohiro Umezu
Project Manager
Tokyo Medical University
Masahiko Kuroda
Founder & Advisor
Tokyo Medical University
Akihiko Umezawa
Founder & Advisor
National Center for Child Health and Development